Double-Blind Study of Dextroamphetamine Versus Caffeine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder
The DOI matches its Crossref record.
Abstract
INTRODUCTION: Two small, double-blind, placebo-controlled, single-dose, crossover studies found dextroamphetamine (d-amphetamine) 30 mg clearly superior to placebo in relieving symptoms of obsessive-compulsive disorder (OCD). We conducted a 5-week, double-blind, caffeine-controlled study to test the hypothesis that d-amphetamine, added after an adequate selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) trial, would be more effective than caffeine in reducing residual OCD symptoms of moderate or greater severity. METHOD: Between August 2006 and February 2008, we enrolled adults with DSM-IV OCD and a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of >or= 20 after >or= 12 weeks of adequate treatment with an SSRI or SNRI. Subjects were randomly assigned to double-blind d-amphetamine 30 mg/d or caffeine 300 mg/d added to their SSRI/SNRI and other medications. Responders (first week mean Y-BOCS score decrease of >or= 20%) entered the study's 4-week double-blind extension phase. RESULTS: We enrolled 24 subjects, 11 women and 13 men, with a mean (SD) age of 40 (13.2) years and mean baseline Y-BOCS scores of 26.5 (4.1) for the d-amphetamine group (n = 12) and 29.1 (4.0) for the caffeine group (n = 12). At the end of week 1, 6 of 12 d-amphetamine subjects (50%) and 7 of 12 caffeine subjects (58%) were responders. At week 5, the responders' mean Y-BOCS score decreases were, for the d-amphetamine group (last observation carried forward), 48% (range, 20%-80%); and, for the caffeine group, 55% (range, 27%-89%). Obsessive-compulsive disorder and depression improvement were independent. The double-blind remained intact. No subject discontinued the study due to side effects. CONCLUSIONS: Larger, double-blind, placebo-controlled trials of both d-amphetamine and caffeine augmentation are needed in OCD subjects inadequately responsive to adequate doses of an SSRI or SNRI. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00363298.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In OCD patients, alertness has been associated with the disorder’s phenotype [26], [27].”
From The rollercoaster of obsessive-compulsive disorder: How chronotype and time of day affect behavioral inhibition in adults with OCD (2025) · cites this paper as [26]
In the citing paper
“although three small clinical trials have shown evidence that the related drug, dexamphetamine, can be effective in OCD (Insel et al. 1983; Joffe et al. 1991; Koran et al. 2009).”
From Dopaminergic drug treatment remediates exaggerated cingulate prediction error responses in obsessive-compulsive disorder (2019) · cites this paper as Koran et al. 2009
Citations
Cited by
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“The findings of a randomised comparator-controlled trial of dextroamphetamine or caffeine augmentation of SSRI or SNRI antidepressants suggest both compounds were beneficial in reducing symptom severity [II] (Koran et al., 2009).”
BackgroundEvidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Caffeine, Mental Health, and Psychiatric Disorders
Lara, D. R. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1378 · Cited by 233
“In contrast, a recent randomized controlled trial showed that caffeine led to clinical response in 7 out of 12 patients with treatment-resistant obsessive compulsive disorder (OCD) and a 55% reduction of symptom score in these responders, which was comparable to d-amphetamine [42].”
BackgroundFontenelle, L. F., Oostermeijer, S., Harrison, B. J., Pantelis, C., & Yücel, M. (2011) · Drugs · doi:10.2165/11591790-000000000-00000 · Cited by 234
“Finally, case reports,([100]) small case series([101]) and a double-blind, 4-week study comparing amphetamine salts with caffeine([102]) suggest that amphetamine salts may help OCD patients, particularly those with hoarding as a symptom.”
BackgroundPharmacological Treatment of Obsessive-Compulsive Disorder
Pittenger, C., & Bloch, M. H. (2014) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2014.05.006 · Cited by 222
“Both dextroamphetamine and caffeine led to significant improvements in refractory patients over 5 weeks [60].”
BackgroundFineberg, N. A., Hollander, E., Pallanti, S., Walitza, S., Grünblatt, E., Dell’Osso, B. M., Albert, U., Geller, D. A., Brakoulias, V., Janardhan Reddy, Y. C., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000314 · Cited by 161
“A subsequent double-blind comparison of SSRI augmentation with d-amphetamine versus high-dose caffeine showed benefit of both drugs (Koran et al., 2009).”
BackgroundFineberg, N. A., Reghunandanan, S., Simpson, H. B., Phillips, K. A., Richter, M. A., Matthews, K., Stein, D. J., Sareen, J., Brown, A., & Sookman, D. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.12.003 · Cited by 150
Drug treatment of obsessive-compulsive disorder
Kellner, M. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.2/mkellner · Cited by 145
Pharmacological Management of Treatment-Resistant Obsessive-Compulsive Disorder
Abudy, A., Juven‐Wetzler, A., & Zohar, J. (2011) · CNS Drugs · doi:10.2165/11587860-000000000-00000 · Cited by 119
“In view of this data, Koran et al.([87]) conducted a double-blind study of dextroamfetamine with caffeine as a control.”
BackgroundIsHak, W. W., Ugochukwu, C., Bagot, K. S., Khalili, D. N., & Zaky, C. (2012) · PubMed · Cited by 151
Involvement of Adenosine A2A Receptors in Depression and Anxiety
Yamada, K., Kobayashi, M., & Kanda, T. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801022-8.00015-5 · Cited by 107
Albert, U., Marazziti, D., Di Salvo, G., Solia, F., Rosso, G., & Maina, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867325666171222163645 · Cited by 90
Treatment-resistant OCD: Pharmacotherapies in adults
van Roessel, P., Grassi, G., Aboujaoude, E. N., Menchón, J. M., Ameringen, M. V., & Rodríguez, C. I. (2022) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2022.152352 · Cited by 112
Self-citationMarble-burying behavior test as a murine model of compulsive-like behavior
Dixit, P. V., Sahu, R. A., & Mishra, D. K. (2020) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2020.106676 · Cited by 88
Augmentation strategies in obsessive–compulsive disorder
Arumugham, S. S., & Reddy, J. Y. C. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.160 · Cited by 81
“…(2009) Glycine (60 mg/day) vs placebo + SSRI 12 weeks 14 OCD patients on stabilized treatment Glycine nonsignificant improvement – poor tolerability [90] Koran et al. (2009) d-amphetamine 30 mg/day vs caffeine 300 mg/day + SSRI/SNRI 5 weeks 24 OCD patients with adequate trial of SSRI/ SNRI Both…”
BackgroundTreatment of Pediatric Obsessive-Compulsive Disorder: A Review
Mancuso, E., Faro, A. L., Joshi, G., & GELLER, D. A. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0040 · Cited by 74
“This finding of equivalent efficacy of caffeine and d -amphetamine could suggest that neither produced an effective pharmacological effect because a placebo effect could not be ruled out as the cause of improvement (Koran et al. 2009).”
Murray, G. K., Knolle, F., Ersche, K. D., Craig, K. J., Abbott, S., Shabbir, S. S., Fineberg, N. A., Suckling, J., Sahakian, B. J., Bullmore, E. T., et al. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05292-2 · Cited by 53
Pharmacotherapeutic Strategies and New Targets in OCD
Pittenger, C. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_204 · Cited by 58
Pharmacological Augmentations of SRIs for Obsessive Compulsive Disorder
Leppink, E. W., & Grant, J. E. (2017) · Wiley eBooks · doi:10.1002/9781118890233.ch16 · Cited by 43
Management of Obsessive-Compulsive Disorder
Seibell, P. J., & Hollander, E. (2014) · F1000Prime Reports · doi:10.12703/p6-68 · Cited by 46
Treatment-refractory obsessive compulsive disorder
Atmaca, M. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.12.004 · Cited by 44
“Koran et al. (2009) conducted a 5- week, double-blind, caffeine-controlled study to test the efficacy of d-amphetamine on OCD patients who had adequate selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) trial and found that this addition became 50%…”
MethodDifferent Views of Anxiety Disorders
Selek, S. (2011) · InTech eBooks · doi:10.5772/1022 · Cited by 39
Barton, S., Karner, C., Salih, F., Baldwin, D. S., & Edwards, S. J. (2014) · Health Technology Assessment · doi:10.3310/hta18500 · Cited by 36
Management and treatment of obsessive–compulsive disorder
Fineberg, N. A., Drummond, L. M., Reid, J. E., Cinosi, E., Carmi, L., & Mpavaenda, D. (2020) · doi:10.1093/med/9780198713005.003.0098 · Cited by 33
Zheng, H., Jia, F., Han, H., Wang, S., Guo, G., Quan, D., Li, G., & Huang, H. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.12.010 · Cited by 28
Early onset obsessive–compulsive disorder: the biological and clinical phenotype
Grassi, G., Cecchelli, C., Mazzocato, G., & Vignozzi, L. (2021) · CNS Spectrums · doi:10.1017/s1092852921000122 · Cited by 28
Clinical Pharmacology of Comorbid Obsessive–Compulsive Disorder in Tourette Syndrome
Neri, V., & Cardona, F. (2013) · International review of neurobiology · doi:10.1016/b978-0-12-411546-0.00013-5 · Cited by 25
Golubchik, P., Sever, J. M., Weizman, A., & Zalsman, G. (2011) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31821f4da9 · Cited by 27
“Recently, a 5-week, double-blind, caffeinecontrolled study found a reduction in OCD symptoms after d-amphetamine addition to SSRIs or serotonin-norepinephrine reuptake inhibitor.(33) It is likely that stimulants, such as MPH, are beneficial in alleviating ADHD as well as TTM symptoms, in some TTM/ADHD patients.”
BackgroundPittenger, C., Brennan, B. P., Koran, L. M., Mathews, C. A., Nestadt, G., Pato, M. T., Phillips, K. A., Rodríguez, C. I., Simpson, H. B., Skapinakis, P., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113853 · Cited by 24
Self-citationPharmacologic treatment of obsessive-compulsive disorder comorbidity
Pallanti, S., & Grassi, G. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.964208 · Cited by 25
“However, a few years ago a double-blind caffeine-controlled study found that stimulating agents such as d-amphetamine and caffeine are both effective in reducing OC symptoms in at least a half of the patients [53].”
BackgroundMaiti, R., Mishra, A., Srinivasan, A., & Mishra, B. R. (2023) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13568 · Cited by 26
Obsessive-Compulsive Disorder: Diagnosis, Epidemiology, Etiology, and Treatment
Sassano-Higgins, S. A., & Pato, M. T. (2015) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.130211 · Cited by 26
Pallanti, S., & Hollander, E. (2013) · CNS Spectrums · doi:10.1017/s1092852913000618 · Cited by 25
Advances in the management of treatment-resistant anxiety disorders
Lanouette, N. M., & Stein, M. B. (2010) · Focus · doi:10.1176/foc.8.4.foc501 · Cited by 15
Naftalovich, H., Tauber, N., & Kalanthroff, E. (2020) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2020.102316 · Cited by 14
G protein βγ subunits play a critical role in the actions of amphetamine
Mauna, J. C., Harris, S. S., Pino, J. A., Edwards, C. M., DeChellis-Marks, M. R., Bassi, C., García‐Olivares, J., Amara, S., Guajardo, F. G., Sotomayor‐Zárate, R., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0387-8 · Cited by 14
Psychotherapy and medication management strategies for obsessive-compulsive disorder
Walsh, K. H., & McDougle (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s13205 · Cited by 17
“112 At this point, stimulant use in OCD would be considered investigational.”
Mitra, S., Miranda, V. S., McMillan, C., Dykes, D., Mucha, M., Marth, T. E., Poe, B., Basu, D. G., & Bult‐Ito, A. (2020) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000570 · Cited by 12
“, 2016), but the role of caffeine in influencing obsessions and compulsions in OCD is currently not well understood (Koran et al., 2009; Shams et al., 2019).”
BackgroundKalanthroff, E., Linkovski, O., Weinbach, N., Pascucci, O., Anholt, G. E., & Simpson, H. B. (2017) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/j.jbtep.2016.03.009 · Cited by 10
Mota, P. M. P. C., Picó‐Pérez, M., & Morgado, P. F. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.12.007 · Cited by 17
Sarris, J. J., Byrne, G. J., Oliver, G., Cribb, L., Blair‐West, S., Castle, D. J., Dean, O. M., Camfield, D., Brakoulias, V., Bousman, C., et al. (2021) · CNS Spectrums · doi:10.1017/s1092852921000638 · Cited by 12
Ameringen, M. V., Fineberg, N. A., Ravindran, A. V., Arnold, P. D., Beaulieu, S., Brakoulias, V., Brietzke, E. M., Dowlati, Y., Drummond, L. M., Ferretti, C. J., et al. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.12.039 · Cited by 14
Dietary quality and nutrient intake in adults with obsessive–compulsive disorder
Nguyen, T. P., Cribb, L., Ng, C. H., Byrne, G. J., Castle, D. J., Brakoulias, V., Blair‐West, S., Oliver, G., Ee, C., Dean, O. M., et al. (2021) · BJPsych Open · doi:10.1192/bjo.2021.1039 · Cited by 12
Abdel-Ahad, P., & Kazour, F. (2015) · Current Clinical Pharmacology · doi:10.2174/15748847113089990060 · Cited by 13
Koyuncu, A., Çelebi, F., Ertekin, E., & Kahn, D. A. (2015) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000070 · Cited by 12
Soufi, E., Shams, J., Zahiroddin, A., & Shekarriz‐Foumani, R. (2019) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_93_19 · Cited by 9
“The results of this study indicate that the use of caffeine has a significant effect on the reduction of OCD (based on the YBOCS), which is in line with other studies including Koran et al.[7] in which caffeine consumption has reduced the severity of OCD based on the YBOCS.”
InfluentialPromising Treatments for Obsessive-Compulsive Disorder: A Call for Additional Research
Koran, L. M., & Aboujaoude, E. N. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170526120916 · Cited by 10
Self-citationTreatment of Psychiatric Comorbidities in Tourette Syndromes
Cardona, F., & Rizzo, R. (2013) · Oxford University Press eBooks · doi:10.1093/med/9780199796267.003.0025 · Cited by 6
Role of nitric oxide in amphetamine-induced sensitization of schedule-induced polydipsic rats
Liu, Y., Tung, C., Lin, P., & Wan, F.-J. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2354-9 · Cited by 6
“Our results also support the potential use of AMPHlike psychostimulants as an adjunctive pharmacological treatment for OCD patients ( Koran et al. 2009 ).”
ResultThe role of fear and dopamine-striatal pathways in grooming
Givon, L., Edut, S., & Klavir, O. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110323 · Cited by 5
“In a similar manner, methylphenidate (King et al., 2017) and D-amphet-amine (Koran et al., 2009) also been reported to improve OCD symptoms.”
Gautam, M. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001716 · Cited by 5
“These were not included because of a lack of at least 2 RCTs analyzing them as augmentation agents (methylphenidate, amphetamine, mirtazapine, and clomipramine).(18,61,68,69) Although ondansetron and celecoxib showed positive results, multiple confounders across all trials limit the availability of data to assess them…”
BackgroundLinkovski, O., Naftalovich, H., David, M., Seror, Y., & Kalanthroff, E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12124075 · Cited by 3
Lapidus, K. A. B., & Gilbert, A. R. (2010) · Child and Adolescent Psychopharmacology News · doi:10.1521/capn.2010.15.5.6 · Cited by 4
A guide to what works for anxiety
Reavley, N. J., Allen, N., Jorm, A. F., Morgan, A. J., Ryan, S., & Purcell, R. (2013) · Cited by 4
Kalanthroff, E., Seror, Y., Sagi, N., Hochman, S., Linkovski, O., Naftalovich, H., & Simpson, H. B. (2025) · Journal of Mood & Anxiety Disorders · doi:10.1016/j.xjmad.2025.100113 · Cited by 2
“In OCD patients, alertness has been associated with the disorder ’ s phenotype [26,27].”
O'Connor, S., Godfrey, K., Reed, S., Peill, J. M., Rohani-Shukla, C., Healy, M. P., Robbins, T. W., de Souza, A. M. F. L. P., Tyacke, R. J., Papasyrou, M., et al. (2025) · Cureus · doi:10.7759/cureus.78171 · Cited by 5
“Recent studies have shown that certain stimulants can also improve OCD symptoms, at least in the short term; there is preliminary evidence suggesting caffeine and dextroamphetamine can improve OCD symptoms individually, as well as nicotine [30-32].”
Approaches to Treatment Resistance
Pallanti, S., Grassi, G., & Cantisani, A. (2012) · Wiley eBooks · doi:10.1002/9781119941125.ch5 · Cited by 2
Mudgal, V., Mishra, S., Gupta, U. D., & Bagul, K. R. (2025) · Cureus · doi:10.7759/cureus.85131 · Cited by 2
“A double-blind study previously reported that D-amphetamine and caffeine augmentation led to symptom improvement in tr-OCD patients, with responders showing a mean Y-BOCS reduction of 48-55% [27].”
Koffein und psychiatrische Erkrankungen
Beiglböck, W. (2016) · Springer eBooks · doi:10.1007/978-3-662-49564-3_6 · Cited by 1
Kombinationen mit Psychopharmaka in der Behandlung von Angst- und Zwangsstörungen
Volz, H. (2009) · Springer eBooks · doi:10.1007/978-3-211-79826-3_8 · Cited by 1
Sadek, J. R. (2018) · Springer eBooks · doi:10.1007/978-3-319-45635-5_3 · Cited by 1
Sachdev, R. A., Ruparelia, R., Reid, J. E., Mpavenda, D., Cinosi, E., & Fineberg, N. A. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108164313.016 · Cited by 2
Examining the effects of caffeine consumption on the severity of body-focused repetitive behaviors
Chesivoir, E. K., & Grant, J. (2022) · Psychiatry Research Communications · doi:10.1016/j.psycom.2022.100090 · Cited by 1
The Treatment of Obsessive-Compulsive Disorder and the Approaches to Treatment Resistance
Pallanti, S., Grassi, G., & Cantisani, A. (2011) · InTech eBooks · doi:10.5772/21517 · Cited by 3
“A possible explanation for the mechanism of this therapeutic effect could be that the increased release of dopamine induced by both drugs may increase D1 receptor stimulation in the prefrontal cortex; this enhancement is associated with improved attention regulation and working memory in patients with ADHD (Arnsten, 2…”
BackgroundObsessive‐Compulsive Disorder: Assessment and Treatment
Abramovitch, A., Elliott, C. M., Wilhelm, S., Steketee, G. S., & Wilson, A. C. (2014) · Wiley eBooks · doi:10.1002/9781118775349.ch51 · Cited by 1
Il trattamento del disturbo ossessivo-compulsivo resistente
Aguglia, A., Albert, U., Cori, D. D., Maina, G., & Bogetto, F. (2011) · Quaderni Italiani di Psichiatria · doi:10.1016/j.quip.2010.12.003
Scarff, J. R. (2014) · The Internet Journal of Psychiatry
Sadek, J. R. (2016) · Springer eBooks · doi:10.1007/978-3-319-39794-8_7
Obsessive-Compulsive Disorder: Overview and Standard Treatment Strategies
Seibell, P. J., Hamblin, R. J., & Hollander, E. (2015) · Psychiatric Annals · doi:10.3928/00485713-20150602-04 · Cited by 1
Current awareness in human psychopharmacology
(2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1063
Sadek, J. R. (2020) · Springer eBooks · doi:10.1007/978-3-030-60766-1_6
Kombinationen mit Psychopharmaka in der Behandlung von Angst- und Zwangsstörungen
Volz, H. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1849-8_8
Treatment of Psychiatric Comorbidities in Tourette Syndrome
Cardona, F., & Rizzo, R. (2022) · Oxford University Press eBooks · doi:10.1093/med/9780197543214.003.0027
Chapter 52. Treatment of Obsessive-Compulsive Disorder
Kayser, R. R., & Simpson, H. B. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as52 · Cited by 1
Voderholzer, U., Rubart, A., Kathmann, N., Staniloiu, A., Kordon, A., & Zurowski, B. (2024) · Springer eBooks · doi:10.1007/978-3-662-67878-7_2
Behandlung bei psychischer und körperlicher Komorbidität
Voderholzer, U., Rubart, A., Kathmann, N., Staniloiu, A., Kordon, A., & Zurowski, B. (2024) · Springer eBooks · doi:10.1007/978-3-662-67878-7_11
Givon, L., Amado, L., Edut, S., & Klavir, O. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107294
Nutraceuticals and obsessive-compulsive disorder therapy
Mohammadi, A. H., Amin, N., Tavousi, S. A., Mahabady, M. K., Aschner, M., & Mirzaei, H. (2026) · Advances in neurotoxicology · doi:10.1016/bs.ant.2026.03.001
Hudak, R., Eken, H. N., & Donahue, C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27446-6.00006-6
Metadata
- Authors
- Koran, L. M., Aboujaoude, E., & Gamel, N. N.
- Affiliations
- Stanford University (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2009-06-30
- Volume
- 70
- Issue
- 11
- Pages
- 1530-1535
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2081132633
- Cited by
- 79
- References
- 0
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 6 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 3 · 2015: 7 · 2014: 8 · 2013: 5 · 2012: 3
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- obsessive-compulsive disorder, d-amphetamine, treatment-resistant OCD, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, Yale-Brown Obsessive Compulsive Scale, adverse effects, treatment discontinuation
- MeSH terms
- Adult, Caffeine, Dextroamphetamine, Double-Blind Method, Drug Administration Schedule, Drug Resistance, Drug Therapy, Combination, Female, Humans, Longitudinal Studies, Male, Middle Aged, Obsessive-Compulsive Disorder, Psychiatric Status Rating Scales, Neurotransmitter Uptake Inhibitors, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.